AVITA Medical Inc (ASX: AVH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AVITA Medical Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AVITA Medical Inc (ASX: AVH)
Latest News
52-Week Highs
7 ASX All Ordinaries shares smashing new 52-week highs today
Share Gainers
Guess which ASX All Ordinaries stock has soared 50% in 3 days after reporting
Share Gainers
3 ASX All Ordinaries shares that defied today's sell-off to leap higher
Healthcare Shares
Is there an $8 billion 'pot of gold at the end of the rainbow' for investors in this ASX healthcare share?
Ask a Fund Manager
2 absolute bargain ASX shares to buy right now: analyst
Share Gainers
3 ASX All Ordinaries shares defying today's rout to surge higher
Earnings Results
Avita share price dives 16% on net loss
Share Gainers
Why is the Avita Medical share price tracking 20% higher today?
Healthcare Shares
Bell Potter names 2 of the best ASX healthcare shares to buy in FY23
Earnings Results
Avita Medical share price tumbles 7% on declining Q1 revenue
Healthcare Shares
4 ASX healthcare shares at 52-week lows
Small Cap Shares
3 promising small cap ASX shares to watch
Frequently Asked Questions
-
No, AVITA Medical does not pay dividends at this time.
-
AVITA Medical Inc listed on the ASX on 24 June 2020.
-
Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.
AVH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About AVITA Medical Inc
AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.
The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993.
RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo.
AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.
AVH Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $4.92 | $0.15 | 3.14% | 58,301 | $4.80 | $4.95 | $4.80 |
26 Mar 2024 | $4.77 | $-0.06 | -1.24% | 63,157 | $4.83 | $4.83 | $4.77 |
25 Mar 2024 | $4.83 | $-0.15 | -3.01% | 60,606 | $4.85 | $4.93 | $4.82 |
22 Mar 2024 | $4.98 | $0.14 | 2.89% | 76,236 | $4.81 | $4.98 | $4.81 |
21 Mar 2024 | $4.84 | $0.01 | 0.21% | 79,808 | $4.85 | $4.90 | $4.81 |
20 Mar 2024 | $4.83 | $-0.03 | -0.62% | 87,103 | $4.86 | $4.89 | $4.78 |
19 Mar 2024 | $4.86 | $-0.24 | -4.71% | 138,063 | $4.89 | $4.89 | $4.77 |
18 Mar 2024 | $5.10 | $0.08 | 1.59% | 68,470 | $5.05 | $5.11 | $5.03 |
15 Mar 2024 | $5.02 | $-0.04 | -0.79% | 100,236 | $5.03 | $5.03 | $4.95 |
14 Mar 2024 | $5.06 | $0.01 | 0.20% | 137,468 | $5.08 | $5.12 | $5.02 |
13 Mar 2024 | $5.05 | $0.06 | 1.20% | 66,603 | $5.05 | $5.09 | $5.03 |
12 Mar 2024 | $4.99 | $-0.09 | -1.77% | 94,363 | $5.09 | $5.09 | $4.95 |
11 Mar 2024 | $5.08 | $-0.02 | -0.39% | 159,928 | $5.13 | $5.14 | $5.03 |
08 Mar 2024 | $5.10 | $0.07 | 1.39% | 71,065 | $5.15 | $5.17 | $5.06 |
07 Mar 2024 | $5.03 | $-0.18 | -3.45% | 262,285 | $5.10 | $5.10 | $4.95 |
06 Mar 2024 | $5.21 | $-0.22 | -4.05% | 84,406 | $5.30 | $5.30 | $5.19 |
05 Mar 2024 | $5.43 | $0.20 | 3.82% | 520,789 | $5.35 | $5.44 | $5.32 |
04 Mar 2024 | $5.23 | $-0.29 | -5.25% | 261,086 | $5.52 | $5.52 | $5.17 |
01 Mar 2024 | $5.52 | $0.40 | 7.81% | 355,080 | $5.48 | $5.62 | $5.38 |
29 Feb 2024 | $5.12 | $-0.36 | -6.57% | 170,224 | $5.12 | $5.18 | $5.03 |
28 Feb 2024 | $5.48 | $0.07 | 1.29% | 276,933 | $5.46 | $5.58 | $5.43 |
27 Feb 2024 | $5.41 | $0.25 | 4.84% | 619,513 | $5.52 | $5.53 | $5.31 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
27 Dec 2023 | James Corbett | Sell | 1,445 | $6,025 |
As advised by the company. sale of 1,445 Common Stock
|
22 Dec 2023 | Jeremy Curnock-Cook | Sell | 2,500 | $30,120 |
As advised by the company. Sale of Common Stock to satisfy personal tax
obligations in relation to the vesting of RSUs in December 2023. |
13 Dec 2023 | Jan Reed | Exercise | 12,589 | $47,334 |
Conversion of securities. 11,958 RSUs
|
13 Dec 2023 | Jan Reed | Issued | 12,589 | $47,334 |
Conversion of securities.
|
13 Dec 2023 | Jeremy Curnock-Cook | Issued | 12,589 | $47,334 |
Conversion of securities.
|
13 Dec 2023 | Jeremy Curnock-Cook | Exercise | 12,589 | $47,334 |
Conversion of securities. 6,175 RSUs
|
13 Dec 2023 | Louis (Lou) Panaccio | Issued | 12,589 | $47,334 |
Conversion of securities.
|
13 Dec 2023 | Louis (Lou) Panaccio | Exercise | 12,589 | $47,334 |
Conversion of securities. 6,175 RSUs
|
13 Dec 2023 | Suzanne Crowe | Exercise | 12,589 | $47,334 |
Conversion of securities. 6,175 RSU
|
13 Dec 2023 | Suzanne Crowe | Issued | 12,589 | $47,334 |
Conversion of securities.
|
07 Jun 2023 | Jeremy Curnock-Cook | Issued | 6,175 | $26,490 |
Issue of securities. 18,764 RSUs
|
07 Jun 2023 | Jeremy Curnock-Cook | Issued | 2,646 | $11,351 |
Issue of options.
|
07 Jun 2023 | Suzanne Crowe | Issued | 6,175 | $26,490 |
Issue of securities. 18,764 RSUs
|
07 Jun 2023 | Suzanne Crowe | Issued | 2,646 | $11,351 |
Issue of options.
|
07 Jun 2023 | Louis (Lou) Panaccio | Issued | 6,175 | $26,490 |
Issue of securities. RSUs 18,764
|
07 Jun 2023 | Louis (Lou) Panaccio | Issued | 2,646 | $11,351 |
Issue of options.
|
07 Jun 2023 | James Corbett | Issued | 100,000 | $429,000 |
Issue of options.
|
07 Jun 2023 | Jan Reed | Issued | 2,646 | $11,351 |
Issue of options.
|
07 Jun 2023 | Jan Reed | Issued | 6,175 | $26,490 |
Issue of securities.
|
07 Jun 2023 | Cary Vance | Issued | 16,549 | $70,995 |
Issue of securities. 16,549 RSUs
|
07 Jun 2023 | Cary Vance | Issued | 7,092 | $30,424 |
Issue of options.
|
07 Jun 2023 | Robert McNamara | Issued | 7,092 | $30,424 |
Issue of options.
|
07 Jun 2023 | Robert McNamara | Issued | 16,549 | $70,995 |
Issue of securities. 16,549 RSUs
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Louis (Lou) James Panaccio | Non-Executive ChairmanNon-Executive Director | Jul 2014 |
Mr Panaccio has served as Non-Executive Chairman of the Board of Directors since July 2014. Mr. Panaccio is a healthcare businessman with extensive experience companies from concept to commercialization. Mr Panaccio possesses more than 35 years of executive leadership experience in healthcare services and life sciences, including more than 25 years of board-level experience. Mr Panaccio is currently a Non-Executive Director of ASX50 company and one of the world's largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005.
|
Professor Suzanne Crowe | Non-Executive Director | Jan 2016 |
Professor Crowe AO has served as a Non-Executive Director since January 2016. Australian-based, she is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, and Emeritus Professor, Monash University Melbourne, she is currently a Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostic company. Past board positions include St. Vincent's Health Australia Ltd (2012-2021), the country's largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia (AO) in 2020 in recognition of her services to health, clinical governance, biomedical research, and education. We believe Professor Crowe is qualified to serve on our board of directors based on her technical experience and extensive expertise in supporting companies with their medical and scientific strategies.
|
Mr Jeremy Curnock-Cook | Non-Executive Director | Oct 2012 |
Mr Curnock Cook has served as a Non-Executive Director of since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr Curnock Cook brings his decades of international experience to our Board of Directors. Over his career, Mr Curnock Cook has managed in excess of US $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr. Curnock Cook co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr. Curncock Cook has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan, and Australia. In addition to serving on our Board of Directors, Mr Curnock Cook serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics appointed February 2012, Sea Dragon appointed October 2012, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, Marine Department Ltd, appointed on January 2019, JLCC Ltd appointed December 2019, CRiL appointed November 2020 and Humanetix appointed September 2021. We believe Mr. Curnock Cook is qualified to serve on our board of directors based on his extensive experience in the life sciences.
|
Dr Michael S Perry | Chief Executive Officer | Feb 2013 |
Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.
|
Ms Jan Stern Reed | Non-Executive Director | Jul 2021 |
Jan Stern Reed has served as a Non-Executive Director since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
|
Mr Cary Vance | Non-Executive Director | Apr 2023 |
Mr Vance has over 25 years of leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of Titan Medical, a position he has held since July 2022. Prior to this appointment, he served as an independent director for Titan Medicals Board of Directors. Previously, Mr Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical and Myoscience. Prior to these roles, he served as President and CEO of Hansen Medical, a publicly held robotics company from 2014 to 2016. Additional executive leadership experience includes roles include at Teleflex, Covidien, and GE Healthcare.
|
Mr Robert McNamara | Non-Executive Director | Apr 2023 |
Mr McNamara is an senior executive with over 25 years of experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics Modulation Technologies and Teknova. Additionally, Mr McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies Accuray, Somnus Medical Technologies, and Target Therapeutics.
|
Mr Mark Andrew Licciardo | Company Secretary | Mar 2018 |
-
|
Mr James Corbett | Chief Executive OfficerPresident | Jul 2021 |
-
|
Erin Liberto | Chief Commercial Officer |
-
|
|
James Corbett | Chief Executive OfficerPresident |
-
|
|
Andrew Quick | Chief Technology Officer |
-
|
|
Mark Andrew Licciardo | Company Secretary |
-
|
|
Donna Shiroma | General Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
The Vanguard Group, Inc. | 5,738,820 | 4.54% |
Pura Vida Investments, LLC | 4,337,590 | 3.43% |
BlackRock Institutional Trust Company, N.A. | 2,341,715 | 1.85% |
Michael Perry | 1,779,235 | 1.41% |
Thorney Investment Group | 1,500,000 | 1.19% |
Australian Eagle Asset Management Pty Ltd | 1,295,235 | 1.02% |
Geode Capital Management, L.L.C. | 1,259,790 | 1.00% |
Renaissance Technologies LLC | 1,192,900 | 0.94% |
Private Clients of Hub24 | 904,150 | 0.71% |
Millennium Management LLC | 901,210 | 0.71% |
Norges Bank Investment Management (NBIM) | 855,815 | 0.68% |
Polar Asset Management Partners Inc. | 768,000 | 0.61% |
Columbia Threadneedle Investments (US) | 748,435 | 0.59% |
XY Capital Limited | 706,830 | 0.56% |
Goldman Sachs International | 662,080 | 0.52% |
Arlene Perry | 631,525 | 0.50% |
MLC Navigator Platform | 592,810 | 0.47% |
Evan Clucas & Leanne Weston | 560,535 | 0.44% |
Caption Management, LLC | 534,795 | 0.42% |
David Deelen | 530,605 | 0.42% |